Migraine headache is associated with increased risk for cardiovascular disease and cerebrovascular events, including ischemic stroke.
Patients receiving intensive low-density lipoprotein-cholesterol-lowering therapy may have better clinical outcomes when their body mass index is normal vs high.
Hypertension, smoking, and the levels of triglycerides were found to be independently associated with the risk for cardiovascular disease in patients with dysbetalipoproteinemia.
Patients with familial combined hyperlipidemia may have more severe pro-atherogenic changes in the presence vs absence of hypertriglyceridemia.
There may be age-related differences in the plasma levels of cholestanol and lathosterol as well as in their respective ratios to cholesterol levels.
The aims of the study were to discover efficacy of bariatric surgery for remission of diseases related to obesity, estimate metabolic changes over 5 years, and compare the outcomes of restrictive and gastric bypass surgeries.
AstraZeneca is discontinuing a phase 3 trial evaluating Epanova in patients with mixed dyslipidemia who are at high risk of CVD.
The adoption of a set of 9 updated public policy recommendations to reduce the clinical and public health burden associated with familial hypercholesterolemia, individual countries can curb atherosclerotic cardiovascular disease in people who carry a gene that predisposes to the disease.
The lowering of lipoprotein(a) with alirocumab was found to independently contribute to the reduction in major adverse cardiovascular events in patients with recent acute coronary syndrome.
High-intensity statin treatment after ischemic stroke or transient ischemic attack is associated with a reduced risk for subsequent cardiovascular events.